GlassScriptPhysician profile
Harpreet Randhawa
NPI 1922016062
$4,094.59
in general payments reported to CMS, 2019-2025
24 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $258 · 2021: $237 · 2022: $388 · 2023: $841 · 2024: $828 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.49 |
| Education | $346.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,367.60 | 2023-2025 | |
| Harmony Biosciences LLC | $510.76 | 2020-2025 | Wakix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $440.07 | 2022-2024 | Lifevest |
| Abbott Laboratories | $316.11 | 2023-2025 | Gallant |
| Inspire Medical Systems, INC. | $237.26 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.19 | 2021-2022 | |
| Abiomed | $139.57 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $123.05 | 2019-2023 | Fasenra |
| Merck Sharp & Dohme LLC | $117.26 | 2019 | |
| Fisher & Paykel Healthcare INC | $106.10 | 2022-2025 | Fisher & Paykel Healthcare |
| Avadel Cns Pharmaceuticals, LLC | $104.21 | 2024-2025 | Lumryz |
| Arbor Pharmaceuticals, INC. | $80.00 | 2019-2021 | |
| Philips North America LLC | $78.85 | 2019-2023 | |
| Resmed Corp | $57.87 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $40.90 | 2022-2023 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $37.39 | 2019 | |
| Radius Health, INC. | $26.05 | 2025 | Tymlos |
| Grifols USA, LLC | $19.78 | 2019 | |
| Lilly USA, LLC | $19.43 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2020 | |
| Almatica Pharma LLC | $14.24 | 2022 | |
| Shire North American Group INC | $13.34 | 2019 | |
| Glaxosmithkline, LLC. | $13.30 | 2019 | |
| Mylan Specialty L.P. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpreet Randhawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.